In the News

Making Medicine The Old-Fashioned Way - NH Chronicle 2009 (Video)

PCCA’s January Pharmacist of the Month - PCAA 2008

Forty Under 40 Who Are Making a Difference - Union Leader 2007

Pharmacists Walk Legal Line - NHPR July 2006

NH 'Compounding' Pharmacy Makes Custom Medicines - Union Leader 2006

As a result of our PCAB-Accreditation for sterile compounding, urologists nationwide work with our pharmacists and staff to compound sterile injectables for their patients with erectile dysfunction (ED).

We compound a variety of Bi-Mix, Tri-Mix (see below), and other sterile injectables formulated to treat this condition. Our standard Tri-Mix formula has been used for years by some of our nation’s leading urologists. According to the book, Erectile Dysfunction, this injection has been reported to be less painful and preferred by patients than other treatments.

Most importantly, all of our injectable ED treatments are prepared in our USP <797>, PCAB-Accredited clean room facility. NNECP is the first and only pharmacy in New England to earn this valuable distinction for urological compounding.

 

“Triple Mix” Injection for Erectile Dysfunction

Men with erectile dysfunction (ED) who used triple therapy (papaverine/phentolamine/prostaglandin-E1) by intracavernosal injection (ICI) and then changed to oral sildenafil found they had a greater preference than expected for triple therapy. Overall, the erection quality with ICI was better than that with sildenafil. (1)

Fear of pain with intracavernosal injection (ICI) therapy may discourage its use. Yet, findings from a Cleveland Clinic study show that in the majority of ED patients, discomfort is minimal. (2)

Treatment with self-injections of vasoactive drugs in men with diabetes (both type 1 and type 2) and severe ED is a safe and effective alternative in the long term. The key is adjustment of the therapeutic method and dosage to optimal levels for satisfactory erections. (3)

Early intracavernosal injections following radical prostatectomy facilitated early sexual intercourse, patient satisfaction and potentially earlier return of natural erections, according to a study from the Glickman Urological Institute, Cleveland Clinic Foundation. Early combination therapy with sildenafil allowed a lower dose of intracavernous injections, minimizing the penile discomfort. (4)

A higher percentage of positive response in patients with erectile dysfunction was achieved with the trimix modality. Choice of more potent ICI regimens can improve efficacy. (5)

1. BJU Int. 2003 Aug;92(3):277-80.
   Preference for oral sildenafil or intracavernosal injection in patients with erectile dysfunction already using intracavernosal injection for > 1 year.
   Click here to access the PubMed abstract of this article.
2. J Sex Med. 2005 May;2(3):428-31.
   Use of a visual analog scale to assess pain of injection with intracavernous injection therapy.
   Click here to access the PubMed abstract of this article.
3. Asian J Androl. 2006 Mar;8(2):219-24.
   Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
   Click here to access the PubMed abstract of this article.
4. Int J Impot Res. 2006 Sep-Oct;18(5):446-51. Epub 2006 Feb 16.
   Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections.
   Click here to access the PubMed abstract of this article.
5. Arch Esp Urol. 2001 May;54(4):355-9.
   [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction]
   Click here to access the PubMed abstract of this article.
   

Resources http://www.ncbi.nlm.nih.gov/pubmed - PubMed U.S. National Library of Medicine National Institutes of Health. NNECP is not responsible for content on third-party websites.